Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1247

Shown on this page

Current sort

Live official records

Conditions: Type 1 Diabetes
Interventions: TZIELD (teplizumab-mzwv); Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 37
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 32 more

Conditions: Necrotizing Enterocolitis
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 2 Weeks to 8 Weeks
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Little Rock, Arkansas • New Haven, Connecticut • Tampa, Florida + 4 more

Conditions: Crohn's Disease (CD)
Interventions: Risankizumab, Ustekinumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 72
States / cities: Chandler, Arizona • Coronado, California • Irvine, California + 62 more

Conditions: Pain, Chronic, Irritable Bowel Syndrome, Symptom Cluster
Interventions: Home-based taVNS intervention; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Lymphocytic Leukemia
Interventions: Venetoclax, Acalabrutinib, Obinutuzumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 32
States / cities: Tucson, Arizona • Clovis, California • Los Angeles, California + 28 more

Conditions: Alcohol Use Disorder
Interventions: NTX-2001, Placebo; Drug
Lead sponsor: Newleos Therapeutics, Inc.; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabete Mellitus
Interventions: FreeStyle Libre 2; Device
Lead sponsor: Abbott Diabetes Care; Industry
Eligibility: 4 Years to 30 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: New Haven, Connecticut • Kansas City, Missouri • Las Vegas, Nevada

Conditions: Postoperative Complications (Cardiopulmonary)
Interventions: Recruited participants receive preoperative rapid submaximal cardiopulmonary exercise testing within the current risk assessment framework of the pre-surgical evaluation clinic; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 45 Years and older
Enrollment: 992 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Ficlatuzumab, Cetuximab, Placebo; Biological · Other
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more

Conditions: Angina, Stable Ischemic Heart Disease
Interventions: Clinician Discretion, Beta blocker, Calcium channel blocker; Other · Drug
Lead sponsor: Yale University; Other
Eligibility: 65 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 10
States / cities: New Haven, Connecticut • Marietta, Georgia • Chicago, Illinois + 5 more

Conditions: Sickle Cell Disease
Interventions: Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more

Conditions: Pneumonia Childhood, Pneumonia, Lung Ultrasound, Antibiotic Stewardship
Interventions: LUNG ULTRASOUND; Diagnostic Test
Lead sponsor: Meyer Children's Hospital IRCCS; Other
Eligibility: 3 Years to 10 Years
Enrollment: 659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: San Diego, California • New Haven, Connecticut • New York, New York + 1 more

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Live official records

Registry for Stage 2 Type 1 Diabetes

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder

FSL2 Post Approval Study for Pediatric and Young Adults Patients

Preoperative Exercise Testing and Perioperative Outcomes

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia

About this Yale institution page